報價延遲最少15分鐘:2025/06/04 00:52 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.8864 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.69/-0.94
|
|
企業價值
25.22M
|
| 資產負債 |
|
每股賬面淨值
26.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 00:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North Americanrights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved EjectionFraction. |